Jazz Pharmaceuticals (JAZZ) EBIT (2010 - 2026)

Jazz Pharmaceuticals' EBIT history runs 17 years deep, the most recent figure standing at $336.6 million for Q1 2026.

• On a quarterly basis, EBIT rose 702.15% year-over-year to $336.6 million in Q1 2026; TTM through Mar 2026 was -$37.7 million, a 106.35% decrease from a year earlier, with the FY2025 full-year figure at -$430.2 million, down 160.04% from the prior year.
• EBIT advanced to $336.6 million in Q1 2026 per JAZZ's latest filing, from $254.5 million in the prior quarter.
• Across five years, EBIT topped out at $336.6 million in Q1 2026 and bottomed at -$686.4 million in Q2 2025.
• The 5-year median for EBIT is $122.5 million (2023), against an average of $66.8 million.
• Across the five-year window, EBIT plunged 633.39% in 2022 and surged 702.15% in 2026, its largest moves.
• Year by year, EBIT stood at -$263.4 million in 2022, then surged by 146.51% to $122.5 million in 2023, then soared by 55.73% to $190.8 million in 2024, then jumped by 33.43% to $254.5 million in 2025, then surged by 32.24% to $336.6 million in 2026.
• Per Business Quant, the three latest JAZZ EBIT figures stand at $336.6 million (Q1 2026), $254.5 million (Q4 2025), and $57.5 million (Q3 2025).